Fidelity Investments
BMY.RT

Fidelity Investments’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Fidelity Investments’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,524,945
Closed -$3.81M – 4793
2020
Q4 		$3.81M Sell
5,524,945
-177
-0% -$377 ﹤0.01% 2245
2020
Q3 		$12.4M Sell
5,525,122
-862,220
-13% -$2.46M ﹤0.01% 1755
2020
Q2 		$22.9M Sell
6,387,342
-1,729,346
-21% -$6.24M ﹤0.01% 1487
2020
Q1 		$30.8M Sell
8,116,688
-4,216,771
-34% -$13.9M ﹤0.01% 1230
2019
Q4 		$37.1M Buy
+12,333,459
New +$32.1M ﹤0.01% 1342

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Fidelity Investments's BMY.RT Position: Q1 2021 in Review

Fidelity Investments sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 5,524,945 shares — an estimated $3.81M sold.

Fidelity Investments first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $37.1M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Fidelity Investments reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Fidelity Investments sold 5,524,945 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $3.81M.
  • Fidelity Investments first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Fidelity Investments's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $37.1M in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Fidelity Investments's 13F filing for Q1 2021, filed 14 May 2021.